Effects of Stigmasterol on Rats with Cuprizone-Induced Neuroinflammation
In a study with 36 Wistar rats, stigmasterol (at doses of 100, 200, or 400 mg/kg/day) was administered for 3 weeks alongside cuprizone to evaluate its effects on cognitive and locomotor functions, as well as inflammatory and antioxidant status. Treatment improved performance, restored antioxidant levels, altered inflammatory marker expression, and increased certain neurotransmitter and MBP concentrations.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
These findings suggest potential therapeutic effects of stigmasterol on neuroinflammation and cognitive function in a rat model, which may have implications for understanding treatments in related conditions.
What this does not prove
The study does not establish the effects in humans; findings are based on a rat model of cuprizone-induced neuroinflammation and demyelination.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 36 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-05
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceStigmasterol attenuates cuprizone-induced neuroinflammation and demyelination in rats through modulation of inflammatory mediators and oxidative stress. ↗DOI: 10.1007/s10787-026-02411-2
Supporting passages (7)
sample sizeMATERIALS AND METHODS: A total of 36 Wistar rats (150-200 g) of both sexes were divided into 6 groups (n = 6) in random manner.
publication date2026-10-05
interventionStigmasterol (100, 200, or 400 mg/kg/day)
comparatorStigmasterol (100, 200, or 400 mg/kg/day) or dimethyl fumarate (15 mg/kg/day) was then administered orally for 3 weeks while cuprizone administration continued.
follow up3 weeks
findingsCompared with cuprizone group, stigmasterol treatment prominently improved cognitive and locomotor performance (P < 0.001), restored antioxidant status (P < 0.001), upregulated the mRNA expression of IL-4, IL-10 and MBP, downregulated expression of IL-1β, TNF-α and IL-6, and increased both neurotransmitter concentrations (P < 0.001) and MBP concentrations in a dose-dependent manner.
limitationsTitle: Stigmasterol attenuates cuprizone-induced neuroinflammation and demyelination in rats through modulation of inflammatory mediators and oxidative stress.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.